|
Dr. Dennis Goldberg is founder, President and Chief Executive Officer of neXus therapeutics, a virtual drug development company. Prior to the formation of neXus, he was Chairman, President, Chief Executive Officer and Founder of Phaedrus Pharmaceuticals, Inc. (formerly called New Drug Associates). Dr. Goldberg has 15 years of experience in the pharmaceutical and biotechnology industries, ranging from drug discovery at a Fortune 25 pharmaceutical company to President and CEO of virtual biotechnology companies. He is currently President and CEO of Biophoretic Therapeutics Systems LLC, a virtual biopharmaceutical company managed by NDA, developing a wireless, personal iontophoresis device to deliver acyclovir to the dermal layer of the skin for the treatment of herpes labialis and other dermatologic conditions. Dr. Goldberg was formerly Vice President for Drug Development and Regulatory Affairs at GelTex Pharmaceuticals (NASDAQ:GELX) and was responsible for all aspects of pre-clinical, non-clinical, clinical and regulatory affairs at GelTex, leading to the submission of an NDA and subsequent marketing approval for RenaGel, the companies first product. Prior to joining GelTex, he was Vice President of Research and Development and Co-founder of Transcend Therapeutics, a publicly traded biotechnology company that was spun out of Clintec Nutrition Company, a joint venture between Baxter Healthcare and Nestle, SA. Dr. Goldberg received his Ph.D. with Distinction in Physiology and Biochemistry from Temple University, where he was a University Fellow. Dr. Goldberg received Post-Doctoral training in the Physiology Department at the University of Pennsylvania as a Fellow of the American Heart Association, and in the Specialized Center of Research on Atherosclerosis at the University of California, San Diego. | 